Table 1. Clinical, functional, and inflammatory characteristics of patients and controls.
| Variables | Nonallergic asthma (n = 21) | Allergic asthma (n = 35) | Healthy controls (n = 9) | P |
|---|---|---|---|---|
| Age (years) | 54.8 (14.8) | 51.7(13.6) | 41.88 | 0.076 |
| Sex (% females) | 57.1% | 51.4% | 88.8% | 0.125 |
| BMI (kg/m2) | 28.7 (4.1) | 27.3 (5.9) | 25.5 (6.48) | 0.353 |
| FEV1 (%) | 83.4 (13.9) | 80 (20.8) | 100.2 (10.74) | 0.013 |
| Serum eosinophils (x109/L) | 0.302 (0.310) | 0.271 (0.239) | 0.095 (0.068) | 0.113 |
| Sputum eosinophils (%) | 10.33 (19.54) | 11.2 (13.01) | 0.77 (1.09) | 0.166 |
| Rhinitis | 61.9% | 82.8% | n/a | 0.080 |
| Nasal polyposis (%) | 28.5% | 20% | n/a | 0.462 |
| Severe persistent asthma (%) | 42.8% | 42.8% | n/a | 0.870 |
| GINA 4.0 scale, grade 5–6 (%) | 52.4% | 48.5% | n/a | 0.590 |
| Good asthma control (ACT >20%) | 19% | 20% | n/a | 0.357 |
| Emergency room visits last 12 months (%) | 28.5% | 11.4% | n/a | 0.182 |
| >1 round of oral corticosteroids last 12 months | 38% | 8.5% | n/a | 0.022 |
| Inflammatory phenotype in induced sputum (%) | Paucigranulocytic: 28.6% | Paucigranulocytic: 22.4% | n/a | 0.425 |
| Mixed: 9.5% | Mixed: 8.6% | |||
| Eosinophilic: 33.3% | Eosinophilic: 54.3% | |||
| Neutrophilic: 28.6% | Neutrophilic: 14.3% |